Skip to main content
. 2022 Jun 16;28:e936497-1–e936497-10. doi: 10.12659/MSM.936497

Table 5.

Clinical, laboratory, and treatment data of ulcerative colitis patients with or without renal involvement.

Ulcerative colitis Patients with renal involvement (n=50) Control group (n=60) p
Age in years at diagnosis (mean±SD) 41.8±15.1 37.9±12.2 0.231

Follow-up period in years (mean±SD) 9.7±6.0 8.9±6.0 0.425

Disease extent, n (%)

Proctitis 11 (22.0) 10 (16.7) 0.706

Left-sided colitis 19 (38.0) 22 (36.7)

Extensive colitis 20 (40.0) 28 (46.6)

Disease activity and treatment, n (%)

Active disease
 Endoscopic active 12 (24.0) 13 (21.7) 0.771
 Clinical active (UCAI ≥120) 15 (30.0) 12 (20.0) 0.225

Anti-TNF use 6 (12.0) 3 (5.0) 0.182

IBD related surgery 3 (6.0) 3 (5.0) 0.579

Laboratory parameters, (mean±SD)

Creatinine (mg/dL) 0.9±0.4 0.8±0.2 0.016

e-GFR (mL/min/1.73 m2) 79.0±25.4 93.8±21.4 0.001

Uric acid (mg/dL) 4.6±1.5 3.9±1.5 0.068

Albumin (g/dL) 4.1±0.4 4.3±0.6 0.006

Hemoglobin (g/dL) 13.1±1.4 13.0±1.7 0.904

ESR (mm/h) 23.1±20.6 20.9±19.6 0.757

CRP (mg/L) 6.5±10.3 7.0±12.7 0.550

CRP – C-reactive protein; ESR – erythrocyte sedimentation rate; e-GFR – estimated glomerular filtration rate; TNF – tumor necrosis factor; UCAI – ulcerative colitis activity index. Significant p values are written in bold.